Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
110 USD | -1.24% |
|
+2.62% | +75.62% |
27/06 | Natera Launches Phase 2 Gastroesophageal Cancer Trial Using Signatera | MT |
27/06 | Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.62% | 13.68B | |
+26.83% | 89.18B | |
-26.09% | 76.11B | |
+1.62% | 27.11B | |
-9.85% | 17.13B | |
-0.14% | 16.83B | |
-0.39% | 15.4B | |
+83.01% | 13.25B | |
-25.79% | 12.83B | |
+25.66% | 12.69B |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- Natera Insider Sold Shares Worth $104,813, According to a Recent SEC Filing